Currency In USD
| Previous Close | 25.13 |
| Open | 25.13 |
| Day High | 25.34 |
| Day Low | 23.58 |
| 52-Week High | 47.65 |
| 52-Week Low | 22.3 |
| Volume | 1.65M |
| Average Volume | 1.02M |
| Market Cap | 2.09B |
| PE | -5.59 |
| EPS | -4.24 |
| Moving Average 50 Days | 26.99 |
| Moving Average 200 Days | 28.55 |
| Change | -1.41 |
Mineralys Therapeutics Announces FDA Acceptance of NDA for Lorundrostat for Treatment of Adults with Hypertension and Topline Explore-OSA Trial Results
GlobeNewswire Inc.
Mar 09, 2026 8:30 PM GMT
– The FDA assigned a PDUFA target action date of December 22, 2026 – – The NDA is based on positive data from a successful clinical program demonstrating favorable safety and blood pressure reduction in adults with hypertension – – Topline results fr
Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on Thursday, March 12, 2026
GlobeNewswire Inc.
Mar 09, 2026 12:00 PM GMT
RADNOR, Pa., March 09, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstruct
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Feb 12, 2026 12:00 AM GMT
RADNOR, Pa., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (